Janssen-Cilag Articles
Expanded indication for Janssen's Zytiga cleared in EU
14 January 2013
Regulatory briefs from Ipsen/Inspiration, Janssen and Astellas
20 November 2012
Janssen-Cilag files for EU approval of bedaquiline in MDR-TB
2 September 2012
5.6% annual growth forecast for multiple myeloma drug market to 2020
21 December 2011
Gilead and Johnson & Johnson get EU backing for HIV drugs Eviplera and Edurant, respectively
29 November 2011
EU approval for Janssen-Cilag’s Zytiga in prostate cancer and Novartis’ Votubia for SEGA
8 September 2011
UK NICE backing for Celgene and Janssen multiple myeloma drugs, Thalidomide and Velcade; FDA fast-tracks Istodax sNDA
20 June 2011
European Commission OKs J&J’s Xeplion for schizophrenia
10 March 2011
Johnson & Johnson’s Invega first antipsychotic for schizoaffective disorder approved in EU
5 January 2011
Basilea told Janssen-Cilag will stop Swiss sales of Zevetera; initiates Ph III testing of isavuconazole with Astellas
13 September 2010
Draft guidance from UK’s NICE recommends Celgene and Janssen Cilag multiple myeloma drugs; Sanofi-Aventis’ Multaq approved for AF
27 August 2010
Despite minimal uptake in Crohn's market, Stelara's premium price will result in nearly $337 million sales in 2018 and briakinumab $130 million
23 February 2010
EMEA recommends Janssen-Cilag’s Regranex not be used in patients with any pre-existing cancer
19 February 2010
Increasing competition from other biologics will continue to erode Enbrel's dominance in the psoriasis drug market, DR report concludes
12 February 2010
UK’s NICE says “no” to Novartis’ Afinitor for advanced RCC and delays Sprycel and Tasigna; Scotland backs Alimta and Stelara
9 February 2010
Bristol-Myers Squibb and Pfizer to file apixaban In Europe; J&J unit submits palmitate for schizophrenia
7 December 2009
PPD to acquire Excel PharmaStudies, hives off compounding business and invests in Celtic
28 October 2009
Janssen-Cilag's Stelara backed by UK’s NICE for moderate-to-severe plaque psoriasis
23 September 2009
Janssen PE drug gets OK in Finland and Sweden
16 February 2009
J&J R&D chief calls for "open innovation"
16 February 2009
Janssen withdraws EU application for Invega
15 January 2009
PDCO meeting sees good news for J&J but a mix for GSK and AZ; Janssen pulls Invega app
12 January 2009
Neuromed's pivotal Ph III NMED-1077 trial completes enrollment
1 December 2008
CHMP positive opinion for Tibotec's Prezista
1 December 2008
EMEA suspends J&J's Ionsys on defects
1 December 2008
Janssen's mixed bag from CHMP meeting
1 December 2008
J&J/Basilea's ceftobiprole gets first European approval as Swissmedic clears it for cSSI
24 November 2008
UK cancer groups turn against Celgene over NICE refusal
10 November 2008
UK govt adopts two-tier NHS for Rx drugs
10 November 2008
J&J launches Doribax in UK
6 October 2008
Hospira's Retacrit maintains Hb as well as Erypo
15 September 2008
EC approves expanded indication for Velcade
15 September 2008
Alkermes/J&J's Vivitrol approved in Russia
11 August 2008
J&J's Doribax gets CHMP OK for NP
9 June 2008
J&J drug: longer time to relapse than quetiapine
12 May 2008
New Rx drug pricing models for UK
21 April 2008
Swissmedic grants PharmaMar
7 April 2008
Ustekinumab: "gold standard" for psoriasis by 2011
18 February 2008
Ustekinumab boosts 12-week PASI-75 scores
11 February 2008
Cilag licenses Alkermes
14 January 2008
German generics see drug majors cut prices
14 January 2008
Millennium to get $40M milestone from Ortho Biotech
7 January 2008
Ustekinumab submitted for marketing review in EU and USA
17 December 2007
Chiesi and Abbott sign drug co-promotion deal
19 November 2007
Japan stock market week to September 24, 2007
1 October 2007
Asche Chiesi and Janssen-Cilag to co-market asthma drugs
27 September 2007
Janssen-Cilag announces job cuts
24 September 2007
Tibotec files TMC125 MAA with EMEA
6 August 2007
J&J submits MAA for doripenem to EMEA
30 July 2007
J&J's Invega approved in UK for schizophrenia
9 July 2007
Ceftobiprole MAA submitted to EMEA
25 June 2007
Invega gets nod from CHMP
7 May 2007
Neuromed licenses ALZA's OROS painkiller
7 May 2007
Ortho Biotech reviews ESA Rxing info with FDA
5 March 2007
UK patient moves to Scotland for cancer drug
22 January 2007
NICE set to confirm negative Velcade stand
30 October 2006
EMEA orphan status for MGI's Dacogen
7 August 2006
Paliperidone effective in schizophrenia
24 July 2006
US FDA approves Alza's IONSYS
29 May 2006
S-P's Temodar, Baxter's Feiba etc OKed in Japan
15 May 2006
J-C submits paliperidone MAA to EMEA
15 May 2006
Ionsys gains EU marketing go-ahead
6 February 2006
CORRECTION: Janssen's Risperdal
22 August 2005
Janssen's Risperdal: long-term QOL benefits
15 August 2005
Cilag gains European nesiritide rights
8 August 2005
Expanded indication for Velcade in EU
9 May 2005
Organon/J&J end Risperdal co-promotion
11 April 2005
UK guide for industry on Rx access in DCs
4 April 2005
German pharma's year of patent expiries
17 January 2005
Alkermes expands Risperdal Consta capacity
17 January 2005
Board appointments at France's LEEM
20 October 2003
Janssen-Cilag's topiramate expected to grow migraine prevention market
29 September 2003
Farmaindustria sues over antipsychotic visas
28 July 2003
Risperdal Consta approved in UK
10 March 2003
First launch of J&J's Risperdal Consta in UK
19 August 2002
Durogesic cleared in UK for chronic pain
3 June 2002
Janssen gets OK for Concerta XL in UK
4 March 2002
Stock Commentary - Tokyo
8 November 2001
Tokyo pharma stocks - week to November 5
7 November 2001
Eisai sets up Spanish sales affiliate
2 November 2001
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
